cefpodoxime cefpodoxime cefpodoxime is an oral, third-generation cephalosporin antibiotic available in the us in various generic preparations. it is active against both gram-positive and gram-negative organisms with notable exceptions including pseudomonas aeruginosa, enterococcus, and bacteroides fragilis. it is typically used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. it also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment. cefpodoximeclinical datatrade namesvantin, othersother namescefpodoxime proxetilahfs/drugs.commonographmedlineplusa698024pregnancycategory au: b1 routes ofadministrationoralatc codej01dd13 (who) legal statuslegal status us: ℞-only pharmacokinetic databioavailability50%protein binding21% to 29%metabolismnegligible. cefpodoxime proxetil is metabolized to cefpodoxime by the liverelimination half-life2 hoursexcretionrenal, unchangedidentifiers iupac name (6r,7r)-7--3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclooct-2-ene-2-carboxylic acid cas number80210-62-4 npubchem cid6335986drugbankdb01416 nchemspider4891496 yunii7r4f94tvgykeggd07650 ychebichebi:3504 nchemblchembl1672 ycomptox dashboard (epa)dtxsid6022765 echa infocard100.210.871 chemical and physical dataformulac15h17n5o6s2molar mass427.45 g·mol−13d model (jsmol)interactive image smiles o=c2n1/c(=c(\cs12nc(=o)c(=n\oc)/c3nc(sc3)n)coc)c(=o)o inchi inchi=1s/c15h17n5o6s2/c1-25-3-6-4-27-13-9(12(22)20(13)10(6)14(23)24)18-11(21)8(19-26-2)7-5-28-15(16)17-7/h5,9,13h,3-4h2,1-2h3,(h2,16,17)(h,18,21)(h,23,24)/b19-8-/t9-,13-/m1/s1 ykey:wyusvomtxwrgek-hbwvyfaysa-n y ny (what is this?) (verify) cefpodoxime inhibits peptidoglycan synthesis in bacterial cell walls. it has an oral bioavailability of approximately 50%, which is increased when taken with food. it has an elimination half-life of 2-3 hours in adults, which is prolonged in renal failure. approved indications include community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections. it was patented in 1980 and approved for medical use in 1989. spectrum of bacterial susceptibility and resistance cefpodoxime has been used to treat gonorrhoea, tonsillitis, pneumonia, and bronchitis. the following minimum inhibitory concentrations have been reported: haemophilus influenzae: ≤0.03 – 1 μg/ml neisseria gonorrhoeae: 0.004 – 0.06 μg/ml streptococcus pyogenes: ≤0.004 – 2 μg/ml brand name zoetis markets cefpodoxime proxetil under the trade name simplicef for veterinary use, finecure, india markets the products under trade name cefpo. vantin (by pfizer) in suspension or tablet form. toraxim (by delta pharma ltd. bangladesh) trucef (by renata limited, bangladesh) tricef (by alkaloid skopje, north macedonia) orelox (by sanofi-aventis) mapdox-cv: cefpodoxime and clavulanic acid combination monotax o (cefpodoxime)/ monotax cv (cefpodoxime and clavulanic acid combination) (by zydus healthcare ltd.) acxime 200/cv (by allencia biosciences, india) postpod-50 (cefpodoxime 50mg/5ml) (by laafon galaxy pharmaceuticals)